BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28360110)

  • 1. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.
    Bertrand CA; Mitra S; Mishra SK; Wang X; Zhao Y; Pilewski JM; Madden DR; Frizzell RA
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L912-L925. PubMed ID: 28360110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
    Sato Y; Thomas DY; Hanrahan JW
    J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
    Larsen MB; Choi JJ; Wang X; Myerburg MM; Frizzell RA; Bertrand CA
    Am J Physiol Lung Cell Mol Physiol; 2021 Dec; 321(6):L1147-L1160. PubMed ID: 34668421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.
    Bertrand CA; Zhang R; Pilewski JM; Frizzell RA
    J Gen Physiol; 2009 Apr; 133(4):421-38. PubMed ID: 19289574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
    Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential contribution of SLC26A9 to Cl(-) conductance in polarized and non-polarized epithelial cells.
    Ousingsawat J; Schreiber R; Kunzelmann K
    J Cell Physiol; 2012 Jun; 227(6):2323-9. PubMed ID: 21809345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative binding affinities of PDZ partners for CFTR: a biochemical basis for efficient endocytic recycling.
    Cushing PR; Fellows A; Villone D; Boisguérin P; Madden DR
    Biochemistry; 2008 Sep; 47(38):10084-98. PubMed ID: 18754678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint.
    Loureiro CA; Matos AM; Dias-Alves Â; Pereira JF; Uliyakina I; Barros P; Amaral MD; Matos P
    Sci Signal; 2015 May; 8(377):ra48. PubMed ID: 25990958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of SLC26A9 in Airways and Its Potential Role in Asthma.
    Ousingsawat J; Centeio R; Schreiber R; Kunzelmann K
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain.
    Chang MH; Plata C; Sindic A; Ranatunga WK; Chen AP; Zandi-Nejad K; Chan KW; Thompson J; Mount DB; Romero MF
    J Biol Chem; 2009 Oct; 284(41):28306-28318. PubMed ID: 19643730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
    Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.
    Dougherty PG; Wellmerling JH; Koley A; Lukowski JK; Hummon AB; Cormet-Boyaka E; Pei D
    J Med Chem; 2020 Dec; 63(24):15773-15784. PubMed ID: 33314931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis.
    Bergbower E; Boinot C; Sabirzhanova I; Guggino W; Cebotaru L
    Cell Physiol Biochem; 2018; 45(2):639-655. PubMed ID: 29402832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression.
    Cheng J; Moyer BD; Milewski M; Loffing J; Ikeda M; Mickle JE; Cutting GR; Li M; Stanton BA; Guggino WB
    J Biol Chem; 2002 Feb; 277(5):3520-9. PubMed ID: 11707463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
    Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
    Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6.
    Cheng J; Guggino W
    PLoS One; 2013; 8(6):e68001. PubMed ID: 23818989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CAL as a negative regulator of DeltaF508-CFTR cell-surface expression: an RNA interference and structure-based mutagenetic approach.
    Wolde M; Fellows A; Cheng J; Kivenson A; Coutermarsh B; Talebian L; Karlson K; Piserchio A; Mierke DF; Stanton BA; Guggino WB; Madden DR
    J Biol Chem; 2007 Mar; 282(11):8099-109. PubMed ID: 17158866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.